About Florida Cancer Specialists & Research Institute, LLC: (Homepage)
Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the national Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Celebrating its 40th year in 2024, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
TNBC Awareness Day: Practice-Changing Treatments Grow Clinicians Confidence in Helping Patients
March 3rd 2023Miguel Pelayo, MD, discusses what he sees as practice-changing treatments for patients with triple-negative breast cancer and how he helps patients feel confident in these new treatments.
Read More
FCS Clinical Trials Lead to FDA Approval of New Targeted Drug for Patients with Mantle Cell Lymphoma
February 14th 2023The FDA has approved the first non-covalent Bruton tyrosine kinase inhibitor for the treatment of relapsed or refractory mantle cell lymphoma in adult patients, based on clinical studies conducted with participation by Florida Cancer Specialists & Research Institute.
Read More
Roundtable Discussion: Komrokji Evaluates Pathology, Risk Assessment, and Therapy for Myelofibrosis
January 14th 2023During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed with participants their approach toward assessing and treating a patient with symptoms possibly indicating primary myelofibrosis.
Read More
Addition of Polatuzumab to R-CHOP Improves Outcomes for Patients With DLBCL
January 10th 2023In an interview with Targeted Oncology, Gustavo Fonseca, MD, FACP, discussed the positive health-related quality of life findings in patients with diffuse large B-cell lymphoma from the POLARIX study.
Read More
Bone Mineral Density a Concern for Common Prostate Cancer Therapy
November 21st 2022Diane Cope, PhD, APRN, BC, AOCNP evaluates the bone health of men with prostate cancer undergoing androgen deprivation therapy in a recently published manuscript, “Nursing Considerations for Androgen Deprivation Therapy and Bone Health in Men Affected by Prostate Cancer."
Read More
Trilaciclib Shows Potential to Lower Chemotherapy-Induced Myelosuppression Episodes in ES-SCLC
November 18th 2022Real-world evidence from Florida Cancer Specialists & Research Institute shows that trilaciclib may reduce the chance of chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer.
Read More
Florida Cancer Specialists & Research Institute, LLC has submitted an application to participate in Medicare’s Enhancing Oncology Care Model, an alternative payment model that aims to address healthcare inequities, reduce costs, and improve and report outcomes for cancer patients.
Read More